{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:57:27Z","timestamp":1764251847418,"version":"3.40.5"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,20]]},"abstract":"<jats:p>Antimitochondrial antibody (AMA) serves as a serological marker for diagnosing primary biliary cholangitis (PBC). However, the association between AMA and prognosis for PBC patients remains unclear. The objective of this study was to investigate the relationship between AMA and cirrhosis in PBC patients. This retrospective study enrolled 225 PBC patients, including 127 with liver cirrhosis and 98 without cirrhosis. AMA was tested by indirect immunofluorescence (IIF) with rat kidney as the substrate. AMA-M2 and M2-3E were detected by line immunoassay (LIA). The overall positivity rate for AMA detection in PBC patients was 80.9%. The positivity rates of IIF-AMA, AMA-M2, and M2-3E were significantly higher in patients with liver cirrhosis than in those without cirrhosis (73.2% vs. 52.0%, 74.0% vs. 51.0%, and 80.3% vs. 60.2%, respectively). In multivariate logistic regression, IIF-AMA (OR: 3.05, 95% CI: 1.59\u20135.87), AMA-M2 (OR: 3.11, 95% CI: 1.61\u20136.01), and M2-3E (OR: 3.29, 95% CI: 1.63\u20136.66) remained significantly associated with an increased incidence of liver cirrhosis. Moreover, in multinomial logistic regression, IIF-AMA (compensated cirrhosis, OR: 3.55, 95% CI: 1.49\u20138.44; decompensated cirrhosis, OR: 2.86, 95% CI: 1.32\u20136.18), AMA-M2 (compensated cirrhosis, OR: 4.74, 95% CI: 1.94\u201311.58; decompensated cirrhosis, OR: 2.51, 95% CI: 1.19\u20135.33), and M2-3E (compensated cirrhosis, OR: 4.92, 95% CI: 1.74\u201313.96; decompensated cirrhosis, OR: 2.91, 95% CI: 1.28\u20136.64) were all found to be associated with different stages of liver cirrhosis. AMA was found to be associated with the occurrence of liver cirrhosis in PBC patients. Additionally, AMA was also related to different stages of liver cirrhosis, including compensated and decompensated cirrhosis.<\/jats:p>","DOI":"10.1097\/md.0000000000035617","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T15:28:32Z","timestamp":1697815712000},"page":"e35617","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Antimitochondrial antibody associated with liver cirrhosis in patients with primary biliary cholangitis"],"prefix":"10.1097","volume":"102","author":[{"given":"Yujiao","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaochan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1059-3116","authenticated-orcid":false,"given":"Aifang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"25906","DOI":"10.1038\/srep25906","article-title":"Evolving trends in female to male incidence and male mortality of primary biliary cholangitis.","volume":"6","author":"Lleo","year":"2016","journal-title":"Sci Rep"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis.","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2020.0028","article-title":"Current understanding of primary biliary cholangitis.","volume":"27","author":"Tanaka","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-2007-1007183","article-title":"Antimitochondrial antibodies in primary biliary cirrhosis.","volume":"17","author":"Leung","year":"1997","journal-title":"Semin Liver Dis"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/j.1365-2036.2006.03172.x","article-title":"Antinuclear antibodies giving the \u201cmultiple nuclear dots\u201d or the \u201crim-like\/membranous\u201d patterns: diagnostic accuracy for primary biliary cirrhosis.","volume":"24","author":"Granito","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis.","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1089-3261(03)00101-6","article-title":"Primary biliary cirrhosis--presentation and diagnosis.","volume":"7","author":"Leuschner","year":"2003","journal-title":"Clin Liver Dis"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hep.28859","article-title":"Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis.","volume":"65","author":"Dahlqvist","year":"2017","journal-title":"Hepatology"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/08916934.2013.801461","article-title":"Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease.","volume":"46","author":"Gatselis","year":"2013","journal-title":"Autoimmunity"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"869018","DOI":"10.3389\/fimmu.2022.869018","article-title":"Anti-mitochondrial antibody titers decrease over time in primary biliary cholangitis patients with ursodeoxycholic acid therapeutic response: a cohort study followed up to 28 Years.","volume":"13","author":"Chang","year":"2022","journal-title":"Front Immunol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases.","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.3748\/wjg.v26.i45.7088","article-title":"Chinese guidelines on the management of liver cirrhosis (abbreviated version).","volume":"26","author":"Xu","year":"2020","journal-title":"World J Gastroenterol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis.","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1572-0241.2002.05620.x","article-title":"Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis?","volume":"97","author":"Joshi","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1515\/cclm-2013-0926","article-title":"The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis.","volume":"52","author":"Hu","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep4.1044","article-title":"Toward solving the etiological mystery of primary biliary cholangitis.","volume":"1","author":"Tanakaa","year":"2017","journal-title":"Hepatol Commun"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2478\/jtim-2021-0008","article-title":"Promyelocytic leukemia antigen expression: a histological marker for primary biliary cholangitis diagnosis?","volume":"9","author":"Papamichalis","year":"2021","journal-title":"J Transl Int Med"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.14309\/ajg.0000000000000765","article-title":"Role of antinuclear antibodies in primary biliary cholangitis.","volume":"115","author":"Levy","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","article-title":"Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis.","volume":"98","author":"Muratori","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.14309\/ajg.0000000000000690","article-title":"Novel anti-hexokinase 1 antibodies are associated with poor prognosis in patients with primary biliary cholangitis.","volume":"115","author":"Reig","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy.","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines.","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:30:44Z","timestamp":1746325844000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":27,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035617","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,10,20]]}}}